Portola Pharmaceuticals (PTLA) Rating Increased to Hold at Zacks Investment Research

Portola Pharmaceuticals (NASDAQ:PTLA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “

How to Become a New Pot Stock Millionaire

A number of other analysts also recently issued reports on PTLA. Oppenheimer set a $80.00 target price on Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, December 13th. BidaskClub raised Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. Citigroup reaffirmed a “buy” rating and issued a $74.00 target price on shares of Portola Pharmaceuticals in a research note on Thursday, December 28th. William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a research note on Monday, January 1st. Finally, ValuEngine raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $67.14.

NASDAQ PTLA opened at $30.91 on Friday. Portola Pharmaceuticals has a one year low of $30.10 and a one year high of $67.10. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.94 and a quick ratio of 5.92. The firm has a market capitalization of $2,021.27, a P/E ratio of -6.43 and a beta of 1.49.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.46) by $0.05. Portola Pharmaceuticals had a negative return on equity of 108.43% and a negative net margin of 1,268.34%. The business had revenue of $9.80 million during the quarter, compared to the consensus estimate of $3.71 million. During the same period last year, the company earned ($0.95) EPS. The company’s revenue for the quarter was down 28.4% on a year-over-year basis. sell-side analysts forecast that Portola Pharmaceuticals will post -4.74 earnings per share for the current year.

In related news, EVP Tao Fu sold 1,135 shares of the firm’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $38.47, for a total transaction of $43,663.45. Following the completion of the sale, the executive vice president now directly owns 18,346 shares of the company’s stock, valued at approximately $705,770.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the stock. Penbrook Management LLC acquired a new stake in shares of Portola Pharmaceuticals during the 4th quarter worth about $209,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Portola Pharmaceuticals during the 4th quarter worth about $355,000. MetLife Investment Advisors LLC acquired a new stake in shares of Portola Pharmaceuticals during the 4th quarter worth about $1,247,000. Endurant Capital Management LP increased its position in shares of Portola Pharmaceuticals by 7.2% during the 4th quarter. Endurant Capital Management LP now owns 107,600 shares of the biopharmaceutical company’s stock worth $5,238,000 after purchasing an additional 7,200 shares during the last quarter. Finally, Kazazian Asset Management LLC increased its position in shares of Portola Pharmaceuticals by 11.6% during the 4th quarter. Kazazian Asset Management LLC now owns 13,657 shares of the biopharmaceutical company’s stock worth $665,000 after purchasing an additional 1,416 shares during the last quarter. 88.44% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Portola Pharmaceuticals (PTLA) Rating Increased to Hold at Zacks Investment Research” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3342253/portola-pharmaceuticals-ptla-rating-increased-to-hold-at-zacks-investment-research.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.

Get a free copy of the Zacks research report on Portola Pharmaceuticals (PTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

XYLO 24-Hour Volume Tops $0.00
XYLO 24-Hour Volume Tops $0.00
Financial Survey: Boot Barn  & Foot Locker
Financial Survey: Boot Barn & Foot Locker
Yelp  versus Weight Watchers  Head-To-Head Contrast
Yelp versus Weight Watchers Head-To-Head Contrast
Reviewing Zynex  & Its Competitors
Reviewing Zynex & Its Competitors
Animecoin Price Reaches $0.0111 on Exchanges
Animecoin Price Reaches $0.0111 on Exchanges
Elcoin   Trading 13% Lower  Over Last 7 Days
Elcoin Trading 13% Lower Over Last 7 Days


Leave a Reply

© 2006-2018 Ticker Report. Google+.